GENFIT (GNFT) Competitors $3.48 -0.15 (-4.13%) As of 09/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. PHAT, TSHA, IOVA, AVXL, IMNM, AVBP, PRAX, GOSS, AKBA, and VALNShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Phathom Pharmaceuticals (PHAT), Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA), Anavex Life Sciences (AVXL), Immunome (IMNM), ArriVent BioPharma (AVBP), Praxis Precision Medicines (PRAX), Gossamer Bio (GOSS), Akebia Therapeutics (AKBA), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors Phathom Pharmaceuticals Taysha Gene Therapies Iovance Biotherapeutics Anavex Life Sciences Immunome ArriVent BioPharma Praxis Precision Medicines Gossamer Bio Akebia Therapeutics Valneva GENFIT (NASDAQ:GNFT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Do insiders and institutionals believe in GNFT or PHAT? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.2% of GENFIT shares are owned by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, GNFT or PHAT? GENFIT has higher revenue and earnings than Phathom Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.30$1.63MN/AN/APhathom Pharmaceuticals$55.25M14.97-$334.33M-$4.73-2.47 Is GNFT or PHAT more profitable? GENFIT has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -289.51%. Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A Phathom Pharmaceuticals -289.51%N/A -90.40% Do analysts rate GNFT or PHAT? GENFIT currently has a consensus target price of $7.00, indicating a potential upside of 98.30%. Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 50.09%. Given GENFIT's higher possible upside, research analysts clearly believe GENFIT is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, GNFT or PHAT? GENFIT has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Does the media prefer GNFT or PHAT? In the previous week, GENFIT had 7 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for GENFIT and 4 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.05 beat GENFIT's score of 0.58 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GENFIT 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGENFIT beats Phathom Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.51M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A20.6375.7726.11Price / Sales2.30442.69544.62124.93Price / Cash51.9044.6737.5461.24Price / Book2.359.6212.876.30Net Income$1.63M-$52.73M$3.29B$271.03M7 Day Performance-18.48%1.81%0.28%-0.14%1 Month Performance-13.90%5.50%2.87%5.82%1 Year Performance-37.85%18.12%65.66%27.63% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT1.645 of 5 stars$3.53-2.8%$7.00+98.3%-34.4%$181.51M$76.77M0.00120News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumePHATPhathom Pharmaceuticals2.4949 of 5 stars$11.48-3.0%$17.50+52.4%-33.9%$839.98M$114.04M-2.43110TSHATaysha Gene Therapies2.1382 of 5 stars$3.02-1.6%$8.29+174.4%+52.2%$837.48M$8.10M-8.88180Positive NewsIOVAIovance Biotherapeutics4.4606 of 5 stars$2.27flat$11.90+424.2%-78.1%$821.41M$164.07M-1.85500AVXLAnavex Life Sciences3.8226 of 5 stars$9.09-3.0%$44.00+384.0%+56.0%$804.83MN/A-15.9540IMNMImmunome2.133 of 5 stars$9.48+2.9%$22.89+141.4%-28.8%$801.68M$12.59M-3.0840Analyst ForecastGap DownAVBPArriVent BioPharma1.7331 of 5 stars$18.95-3.9%$39.14+106.6%-25.7%$799.61MN/A-4.7140Positive NewsPRAXPraxis Precision Medicines2.1011 of 5 stars$40.45+7.3%$85.88+112.3%-15.5%$793.69M$7.77M-3.29110Gap DownGOSSGossamer Bio3.9408 of 5 stars$3.18-8.1%$8.50+167.3%+182.8%$786.74M$40.24M-5.13180AKBAAkebia Therapeutics3.8063 of 5 stars$2.92-1.0%$6.75+131.2%+105.3%$782.18M$160.18M-17.18430Positive NewsVALNValneva2.6023 of 5 stars$8.93-0.1%$15.00+68.0%+63.9%$768.19M$183.52M-9.11700Gap Down Related Companies and Tools Related Companies Phathom Pharmaceuticals Alternatives Taysha Gene Therapies Alternatives Iovance Biotherapeutics Alternatives Anavex Life Sciences Alternatives Immunome Alternatives ArriVent BioPharma Alternatives Praxis Precision Medicines Alternatives Gossamer Bio Alternatives Akebia Therapeutics Alternatives Valneva Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
